Home >> Marketplace Archives >> Quest acquires two Texas labs, 7/17

Quest acquires two Texas labs, 7/17

Print Friendly, PDF & Email


July 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Tex., with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty Health; Texas Oncology; and Pathologists Bio-Medical Laboratories are co-owners of one or both businesses.

Once the transaction is complete, which is expected in the third quarter of this year subject to regulatory approvals, Quest will become a preferred provider of oncology diagnostics for the Network, including Texas Oncology. The Network consists of more than 400 locations in the U.S. with more than 1,400 independent, community-based physicians. Quest will provide genomic and pathology testing, such as tumor sequencing. Inherited genetic testing, such as for BRCA breast cancer screening, will not be part of a preferred provider relationship.

Quest will also be a preferred provider of a full range of inpatient and outpatient diagnostic services for 12 Baylor Scott & White Health hospitals in North Texas. Quest and PBM will also have a preferred provider relationship for several services.

McKesson Specialty Health, with the Network and Texas Oncology, plan to collaborate with Quest on the development of standardized, evidence-based services for guiding treatment decisions within the electronic patient record and care plan workflow, building off a model spearheaded by Med Fusion.

Quest Diagnostics, 973-520-2700


Check Also

Veracyte, Quest agreement, 5/17

May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.